Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Rapid progression to death after hepatocellular carcinoma diagnosis particularly among persons with advanced HIV disease in Kampala, Uganda

View ORCID ProfileSara K. Nsibirwa, Jim Aizire, David L. Thomas, Ponsiano Ocama, Gregory D. Kirk
doi: https://doi.org/10.1101/2022.06.24.22276850
Sara K. Nsibirwa
12, Kampala, Uganda
2Infectious Diseases Institute (IDI), Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sara K. Nsibirwa
  • For correspondence: gdk{at}jhu.edu snsibirwa{at}idi.co.ug
Jim Aizire
12, Kampala, Uganda
3Johns Hopkins University, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Thomas
12, Kampala, Uganda
3Johns Hopkins University, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ponsiano Ocama
12, Kampala, Uganda
4Makerere University College of Health Sciences, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory D. Kirk
12, Kampala, Uganda
3Johns Hopkins University, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gdk{at}jhu.edu snsibirwa{at}idi.co.ug
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background HIV infection is associated with more rapid progression of some comorbidities. This study assessed the impact of HIV-infection where the presentation and outcome of HCC was different in persons living with HIV (PLWH) compared to those without HIV infection.

Methods HCC patients attending the Mulago National Referral Hospital in Uganda were enrolled into a natural history study of HCC between March 2015 and February 2019. Standardized methods were used to collect clinical, ultrasound and laboratory data at enrolment. HCC cases were confirmed based on a combination of clinical, ultrasound, tumor marker and pathology data. Follow-up contact was made at one, three, six, and twelve months post-enrolment to determine vital status. Symptoms and signs at diagnosis and subsequent survival were compared by HIV status. Kaplan Meier curves were used to assess HCC survival.

Results Of 441 persons with HCC, 383 (87.0%) died within 12 months following HCC diagnosis. The median (IQR) survival was 42 (20, 106) days. The most commonly reported symptom clusters were pain (80%), gastrointestinal symptoms (28%) and anorexia / cachexia (10%), and no differences were detected in these presenting symptoms (nor most other initial findings) in the 79 (18%) PLWH compared to those without HIV. After adjusting for baseline demographic and clinical characteristics, HIV infection was associated with increased mortality but only among those with severe HIV-associated immunosuppression (CD4 count <200 cells per cubic milliliter), aHR (95% C) = 2.12 (1.23-3.53), p=0.004, and not among PLWH with ≥200 CD4 cells per cubic milliliter, aHR (95% C) = 1.15 (0.82-1.60), p=0.417.

Conclusion Among relatively young Ugandans, HCC is a devastating disease with rapid mortality that is especially rapid among PLWH. HIV was associated with slightly higher mortality, notably among PLWH with lower CD4 cell counts. As a substantial majority of PLWH diagnosed with HCC were engaged in HIV care, further investigation should determine the effectiveness of incorporating screening and early identification of HCC among high-risk individuals into existing HIV care programs. Concurrent with growing access to curative localized treatment for HCC in sub-Saharan Africa, leveraging HIV care infrastructure affords opportunities for earlier HCC intervention.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by grant U54-CA190165 from the National Cancer Institute.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Boards of Makerere University School of Medicine and Johns Hopkins University gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The title has been revised

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 30, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Rapid progression to death after hepatocellular carcinoma diagnosis particularly among persons with advanced HIV disease in Kampala, Uganda
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rapid progression to death after hepatocellular carcinoma diagnosis particularly among persons with advanced HIV disease in Kampala, Uganda
Sara K. Nsibirwa, Jim Aizire, David L. Thomas, Ponsiano Ocama, Gregory D. Kirk
medRxiv 2022.06.24.22276850; doi: https://doi.org/10.1101/2022.06.24.22276850
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Rapid progression to death after hepatocellular carcinoma diagnosis particularly among persons with advanced HIV disease in Kampala, Uganda
Sara K. Nsibirwa, Jim Aizire, David L. Thomas, Ponsiano Ocama, Gregory D. Kirk
medRxiv 2022.06.24.22276850; doi: https://doi.org/10.1101/2022.06.24.22276850

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • HIV/AIDS
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)